关键词： ApoE, apolipoprotein E CEUMI, contrast-enhanced ultrasound molecular imaging CVD, cardiovascular disease GLP, glucagon-like peptide GLP-1R, glucagon-like peptide-1 receptor GLP-1RA, glucagon-like peptide-1 receptor agonist HDL-C, high-density lipoprotein cholesterol HbA1c, glycated hemoglobin ICAM, intercellular cell adhesion molecule IL, interleukin LDL-C, low-density lipoprotein cholesterol MB, microbubble MBCtr, control microbubbles MBVCAM-1, microbubbles targeted to VCAM MCP, monocyte chemoattractant protein OPN, osteopontin TG, triglycerides TGRL, triglyceride-rich lipoproteins TNF, tumor necrosis factor VCAM, vascular cell adhesion molecule VLDL-C, very low-density lipoprotein cholesterol atherosclerosis liraglutide molecular imaging ultrasound

来  源：   DOI：10.1016/j.jacbts.2022.08.002   PDF(Pubmed)

Abstract：
The authors determined the effect of the GLP-1 receptor agonist liraglutide on endothelial surface expression of vascular cell adhesion molecule (VCAM)-1 in murine apolipoprotein E knockout atherosclerosis. Contrast-enhanced ultrasound molecular imaging using microbubbles targeted to VCAM-1 and control microbubbles showed a 3-fold increase in endothelial surface VCAM-1 signal in vehicle-treated animals, whereas in the liraglutide-treated animals the signal ratio remained around 1 throughout the study. Liraglutide had no influence on low-density lipoprotein cholesterol or glycated hemoglobin, but reduced TNF-α, IL-1β, MCP-1, and OPN. Aortic plaque lesion area and luminal VCAM-1 expression on immunohistology were reduced under liraglutide treatment.
摘要：
作者确定了GLP-1受体激动剂利拉鲁肽对小鼠载脂蛋白E敲除动脉粥样硬化中血管细胞粘附分子（VCAM）-1内皮表面表达的影响。使用靶向VCAM-1的微泡和对照微泡的对比增强超声分子成像显示，在媒介物处理的动物中，内皮表面VCAM-1信号增加了3倍，而在利拉鲁肽治疗的动物中,信号比在整个研究过程中保持在1左右.利拉鲁肽对低密度脂蛋白胆固醇或糖化血红蛋白无影响,但降低了TNF-α,IL-1β,MCP-1和OPN。在利拉鲁肽治疗下，免疫组织学上的主动脉斑块病变面积和管腔VCAM-1表达减少。
公众号